Her2/neu-targeting Lytic Peptide Conjugates for Membrane Disruption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer, particularly those expressing Her2/neu, face challenges in effectively targeting and inhibiting cell proliferation and metastasis, especially in multi-drug resistant cells and those with distant metastatic disease, where existing therapies show limited efficacy.
Innovation Solution
Development of lytic peptide and Her2/neu ligand conjugates that disrupt cell membranes, allowing for targeted killing of Her2/neu-expressing cells, regardless of their division status, using specific peptide sequences and linkers to ensure non-immunogenic and effective delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatments are used, then some tumor cells are killed, but multi-drug resistant cells and metastatic cells survive with limited efficacy
Solution Approach 1:
The treatment approach is segmented into two functional domains: a Her2/neu-targeting ligand domain for specific recognition and binding to cancer cells, and a lytic peptide domain for membrane disruption and cell lysis. This segmentation allows the first domain to provide targeted delivery while the second domain executes the cytotoxic function, overcoming drug resistance through a novel mechanism of action that bypasses conventional drug resistance pathways
Solution Approach 2:
The invention creates a composite therapeutic molecule by fusing the Her2/neu ligand (such as affibody molecule ZHER2:2395) with a lytic peptide sequence (such as LAKLAK or RKLFamide). This composite structure combines the targeting capability of the ligand with the membrane-disrupting capability of the peptide, creating a unified therapeutic agent that simultaneously provides specific targeting and effective cell killing, thereby improving reliability against resistant and metastatic cells
2Reliability
If large antibody conjugates are used, then targeting specificity is achieved, but immunogenicity increases
Solution Approach 1:
The invention extracts only the essential functional portions of conventional antibodies: the Her2/neu-binding capability is isolated into a compact affibody molecule (approximately 7 kDa, 63 amino acids) rather than using the full antibody structure. This extracted targeting domain maintains high specificity for Her2/neu-expressing cells while being significantly smaller and less immunogenic than complete antibodies, thereby reducing harmful immunogenic effects while preserving targeting reliability
Solution Approach 2:
The affibody molecule serves as a small, transient targeting component that delivers the lytic peptide to the cell surface and then is shed or degraded. This short-lived targeting moiety performs its function of directing the cytotoxic peptide to the target cell and then disappears, minimizing the persistence of foreign protein structures that could trigger immune responses, thus reducing immunogenicity while maintaining targeting effectiveness
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugates effectively reduce or inhibit cell proliferation and induce apoptosis in Her2/neu-expressing cells, including multi-drug resistant and metastatic cells, offering a potential treatment for various cancers with improved survival rates and reduced metastasis.
Implementation Method 1
Contact of a cell with a lytic domain is believed to cause disruption of the cell membrane which results in cell death
Implementation Method 2
The ligand that binds to Her2/neu targets cells that express Her2/neu for destruction
Data Source
AI summary
The invention relates to conjugates that bind to Her2/neu, methods of using conjugates that bind to Her2/neu and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express Her2/neu.